Introduction

In a monumental step for Vietnam's healthcare landscape, Takeda Pharmaceutical Company has marked its 10-year presence in the country with the recent approval of its dengue vaccine. This significant milestone not only highlights Takeda's unwavering commitment to improving public health but also establishes it as the sole manufacturer and importer of the dengue vaccine within Vietnam.

Company Journey and Future Directions

During a recent trip to Vietnam in September, Dion Warren, the Area Head of India & Southeast Asia (I-SEA), discussed the company's journey in the country, emphasizing its impact on public health and outlining future directions.

Healthcare Challenges in Vietnam

Vietnam's rapid growth and increasing population have led to rising healthcare demands. As the country continues to industrialize, it faces immense challenges posed by both communicable and non-communicable diseases, exacerbated by climate change. Despite significant advancements in the healthcare system, there remains a pressing need for strategic collaborations among stakeholders to enhance disease awareness, improve diagnostic capabilities, and expand access to innovative treatments.

Takeda-ism Philosophy

What sets Takeda apart from other pharmaceutical companies in Vietnam is its guiding philosophy known as Takeda-ism, which prioritizes integrity, fairness, honesty, and perseverance. This framework of values underpins their decision-making process, emphasizing the importance of patient care and fostering trust—an approach that resonates globally while accommodating local needs.

Achievements and Partnerships

Reflecting on its achievements over the past decade, Takeda takes pride in its commitment to delivering innovative treatments. The company has strategically cultivated public and private partnerships to enhance patient access to advanced therapies for rare diseases such as hereditary angioedema and hemophilia. Its involvement in organizations like the Japan Pharmaceutical Manufacturers Association (JPMA) and EuroCham Vietnam underscores its dedication to collaboration and innovation in the healthcare sector.

Dengue Vaccine Approval

The approval of Takeda's dengue vaccine by Vietnam's Ministry of Health in May 2024 stands as a testament to the company’s commitment to combating the growing public health crisis posed by dengue fever, a disease that affects nearly half of the global population, particularly in Southeast Asia. This vaccine launch is not just a response to increasing dengue outbreaks; it is a crucial component of a broader integrated strategy aimed at reducing the disease's burden.

Historical Context

Historically, Takeda has been a long-time provider of high-quality vaccines in Japan, and its foray into global vaccine development is an effort to tackle some of the world's most pressing infectious diseases. The dengue vaccine will be a game-changer, particularly in remote areas and among high-risk groups in Vietnam.

Commitment to Access and Awareness

To ensure widespread access, Takeda is actively working to strengthen partnerships with local authorities, academic institutions, and healthcare professionals. The company is committed to raising awareness about dengue, advocating for sustainable management practices, and providing comprehensive training for healthcare staff in vaccination techniques.

Conclusion

As Vietnam navigates its healthcare challenges, Takeda stands poised to make a lasting impact on public health, ultimately enhancing the quality of life for its citizens. This milestone not only represents a success for Takeda but also promises a healthier future for Vietnam as it continues to fight against formidable healthcare adversities.